According to the latest data from the Hong Kong Stock Exchange, on May 21, BlackRock increased its holdings in Innovent Bio (01801) by 369,453 shares. The transaction was executed at an average price of approximately HK$82.07 per share, amounting to a total consideration of about HK$30.32 million. Following this acquisition, BlackRock's total shareholding in the company has risen to approximately 87.28 million shares, representing a stake of 5.02%.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.